All Practice Exams

100+ Free ABPath Clinical Pathology Practice Questions

Pass your American Board of Pathology Clinical Pathology Primary Certification Examination exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
Varies by year Pass Rate
100+ Questions
100% Free
1 / 100
Question 1
Score: 0/0

A 65-year-old has a peripheral blood smear showing smudge cells and small mature lymphocytes with scant cytoplasm and clumped chromatin. Flow cytometry: CD19+, CD5+, CD23+, CD20 dim, kappa/lambda light chain restricted. Diagnosis?

A
B
C
D
to track
2026 Statistics

Key Facts: ABPath Clinical Pathology Exam

330

Total Questions

Combined Written/Practical (2026 blueprint)

~6h 36m

Total Exam Time

One-day computer-based via Pearson VUE

$2,100

CP-Only Fee (2026)

$2,600 for combined AP/CP in same window

25%

Hematopathology Weight

Largest domain on 2026 blueprint

23%

Blood Banking + Microbiology

Each contributes 23% of the exam

3-4 yrs

ACGME Residency

CP-only 3 yr, combined AP/CP 4 yr

The ABPath CP exam tests 330 one-best-answer questions over ~6.6 hours in one day. The 2026 blueprint (effective January 2026) allocates Hematopathology 25%, Blood Banking/Transfusion Medicine 23%, Medical Microbiology 23%, Chemical Pathology 20%, and Management/Informatics 9%. Molecular pathology questions are integrated across all five domains (10-15% of exam). Fee: $2,100 CP-only or $2,600 combined AP/CP. Eligibility requires completion of ACGME-accredited CP residency (3 years) or AP/CP residency (4 years) with unrestricted medical license. Exam scheduling via Pearson VUE during May/June (Spring) and October (Fall) windows.

Sample ABPath Clinical Pathology Practice Questions

Try these sample questions to test your ABPath Clinical Pathology exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 65-year-old has a peripheral blood smear showing smudge cells and small mature lymphocytes with scant cytoplasm and clumped chromatin. Flow cytometry: CD19+, CD5+, CD23+, CD20 dim, kappa/lambda light chain restricted. Diagnosis?
A.Chronic lymphocytic leukemia (CLL)
B.Mantle cell lymphoma
C.Follicular lymphoma
D.Hairy cell leukemia
Explanation: CLL/SLL: CD19+, CD5+, CD23+, CD20 dim, CD200+, weak surface immunoglobulin light chain restriction. Smudge (Gumprecht) cells are fragile CLL cells. Mantle cell is also CD5+ but CD23- and cyclin D1+/t(11;14)+. Prognostic markers: IGHV mutation status, del(17p)/TP53 (bad), del(13q) (good).
2A 35-year-old woman has microcytic anemia (Hb 9.5 g/dL, MCV 68 fL). Iron studies show low serum iron, low ferritin, high TIBC, and low transferrin saturation (<10%). Most likely diagnosis?
A.Iron deficiency anemia
B.Anemia of chronic disease
C.Thalassemia trait
D.Sideroblastic anemia
Explanation: Iron deficiency anemia: low serum iron, low ferritin (<30 ng/mL is diagnostic; <15 virtually diagnostic), HIGH TIBC, low transferrin saturation (<20%). Anemia of chronic disease: low iron with LOW TIBC and normal-to-high ferritin. Thalassemia has normal iron studies with low MCV and high RBC count.
3Hemoglobin electrophoresis on a Black patient with microcytic anemia shows HbA 85%, HbA2 5.5%, HbF 2%. Diagnosis?
A.Normal
B.Beta-thalassemia minor (trait)
C.Sickle cell trait
D.Hereditary persistence of fetal hemoglobin
Explanation: Beta-thalassemia minor (trait): elevated HbA2 (>3.5%, typically 4-6%) ± mild HbF elevation, microcytic RBCs with normal iron studies, high RBC count, and Mentzer index <13 (MCV/RBC). Normal HbA2 is 2-3%. Alpha thalassemia trait has normal HbA2. HPFH has markedly elevated HbF with normal HbA2.
4A peripheral smear shows schistocytes, platelets <20 × 10⁹/L, and the patient has acute neurologic symptoms and renal injury. ADAMTS13 activity is <10%. Diagnosis?
A.Disseminated intravascular coagulation
B.Thrombotic thrombocytopenic purpura (TTP)
C.Heparin-induced thrombocytopenia (HIT)
D.Hemolytic uremic syndrome (typical, Shiga toxin)
Explanation: TTP is defined by severe ADAMTS13 deficiency (activity <10%) with acquired inhibitory autoantibodies or congenital (Upshaw-Schulman) deficiency. The classic pentad (fever, MAHA, thrombocytopenia, renal injury, neurologic changes) is rarely complete — thrombocytopenia + MAHA with schistocytes plus ADAMTS13 <10% diagnoses TTP. Treatment: plasma exchange, steroids, caplacizumab, rituximab.
5A patient on IV heparin develops a platelet count drop from 250 to 85 × 10⁹/L after 7 days with new DVT. 4Ts score is 7. Which HIT test should be ordered first?
A.Heparin-platelet factor 4 (PF4) ELISA (anti-PF4/heparin antibodies) as screening, followed by serotonin release assay (SRA) if positive/intermediate
B.Platelet function tests only
C.D-dimer
D.Fibrinogen level
Explanation: 4Ts score ≥6 is high probability for HIT. Lab workup: screening with anti-PF4/heparin IgG ELISA (sensitive but not specific — high OD values >1.0 are more predictive); confirm with functional serotonin release assay (SRA) or heparin-induced platelet aggregation. Stop ALL heparin (including flushes, LMWH) and start non-heparin anticoagulation (argatroban, bivalirudin, fondaparinux).
6A bone marrow aspirate shows 30% blasts with prominent Auer rods, MPO+, and cytogenetics t(8;21)(q22;q22) RUNX1-RUNX1T1. Diagnosis per WHO 2022?
A.APL with PML-RARA
B.AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
C.CML accelerated phase
D.B-ALL
Explanation: AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (AML1-ETO) is a core-binding factor AML — favorable risk. Classically shows Auer rods, myeloid maturation, and is CD34+, CD117+, MPO+, HLA-DR+, aberrant CD19+ and/or CD56+. inv(16) is the other CBF AML with eosinophilic component. KIT mutations within CBF AML worsen prognosis.
7A 62-year-old has polycythemia (Hb 19 g/dL), splenomegaly, and leukocytosis. JAK2 V617F is positive. Erythropoietin level is low. Most likely diagnosis?
A.Polycythemia vera (JAK2+, low EPO)
B.Secondary polycythemia
C.Essential thrombocythemia
D.Primary myelofibrosis
Explanation: Polycythemia vera: JAK2 V617F in ~95% (or JAK2 exon 12 mutation in remaining), low serum EPO, Hb >16.5 men/16 women or Hct >49%/48%. Bone marrow hypercellular with trilineage proliferation. Major WHO criteria + minor (low EPO) diagnose PV. Treatment: phlebotomy to Hct <45%, low-dose aspirin, ± hydroxyurea or ruxolitinib for high risk.
8The Coombs direct antiglobulin test (DAT) detects:
A.Free antibodies in patient plasma against RBC antigens
B.Antibodies already bound to the patient's red blood cells (in vivo coating)
C.HLA antibodies
D.Platelet antibodies
Explanation: Direct antiglobulin test (DAT, direct Coombs) detects antibody/complement coating patient RBCs in vivo — positive in autoimmune hemolytic anemia (warm IgG AIHA, cold IgM+C3 CAD), drug-induced hemolysis, hemolytic disease of the newborn (HDN), and hemolytic transfusion reactions. Indirect Coombs (IAT) detects unbound antibodies in plasma (used for antibody screen and crossmatch).
9A patient has an elevated PT and INR but a normal aPTT. Which factor deficiency is most likely?
A.Factor VIII
B.Factor VII (extrinsic pathway)
C.Factor IX
D.Factor XII
Explanation: PT (extrinsic/common pathway) tests factors VII, X, V, II (prothrombin), fibrinogen. aPTT (intrinsic/common) tests XII, XI, IX, VIII, X, V, II, fibrinogen. Isolated PT prolongation with normal aPTT = factor VII deficiency (shortest half-life, first affected by warfarin and liver disease). VIII or IX deficiency (hemophilia A/B) prolongs aPTT with normal PT.
10A mixing study (patient plasma 50:50 normal plasma) corrects a prolonged aPTT. This indicates:
A.Factor deficiency
B.Inhibitor/antiphospholipid antibody
C.Lupus anticoagulant
D.Heparin contamination
Explanation: Correction of prolonged aPTT on immediate mixing = factor deficiency (normal plasma supplies the missing factor). Failure to correct = inhibitor (factor-specific antibody or lupus anticoagulant). Incubated (1-hr 37°C) mixing study may unmask factor VIII inhibitor (time-dependent). Heparin contamination is detected by protamine or chromogenic anti-Xa.

About the ABPath Clinical Pathology Exam

The ABPath Clinical Pathology examination is a one-day computer-based primary certification exam delivered at Pearson VUE Professional Testing Centers. It consists of 330 one-best-answer multiple-choice questions in a combined Written/Practical format, covering five content domains: Hematopathology (25%), Blood Banking/Transfusion Medicine (23%), Medical Microbiology (23%), Chemical Pathology (20%), and Management/Informatics (9%). Practical questions include graphs, charts, formulas, diagrams, electropherograms, red cell antibody panels, and calculations. Candidates are assessed on problem-solving, interpretation of laboratory data, molecular correlations, and application of current guidelines.

Questions

330 scored questions

Time Limit

~6 hours 36 minutes (combined Written/Practical sections)

Passing Score

Criterion-referenced scaled standard (modified Angoff). Pass/fail determined in a single administration.

Exam Fee

$2,100 CP-only / $2,600 combined AP/CP (ABPath 2026) (American Board of Pathology (ABPath) — administered via Pearson VUE)

ABPath Clinical Pathology Exam Content Outline

25%

Hematopathology

RBC disorders (iron deficiency, thalassemia, sickle cell), AIHA DAT patterns, TTP/ADAMTS13 <10%, HIT 4Ts + PF4/SRA, DIC, factor deficiencies (PT vs aPTT interpretation, mixing studies), AML with recurrent genetics (APL t(15;17), CBF, CML BCR-ABL), MPN (JAK2 V617F, CALR, MPL), MDS with del(5q), myeloma IMWG CRAB/SLiM, CLL/SLL flow, B-ALL TdT+/CD10+.

23%

Blood Banking / Transfusion Medicine

ABO/H antigen genetics, DAT (warm IgG vs cold IgM+C3), antibody ID panel, compatibility/crossmatch, massive transfusion 1:1:1 (PROPPR), transfusion reactions (AHTR clerical error, DHTR anamnestic Kidd, TRALI HLA/HNA, TACO), platelet thresholds (10k proph, 20k fever, 50k procedures, 100k neuro), FFP 10-15 mL/kg, cryoprecipitate (fibrinogen/VIII/XIII/vWF), leukoreduced/irradiated/washed indications, Rh prophylaxis RhIG, apheresis ASFA category I-IV (TTP, GBS, MG), HPC DMSO cryopreservation, FDA 2023 donor deferral.

23%

Medical Microbiology

Bacteriology Gram staining + biochemicals (catalase, coagulase, optochin, bacitracin, PYR), MRSA mecA/cefoxitin, VRE vanA/vanB, CRE (KPC vs NDM/VIM/OXA — ceftaz-avibactam, cefiderocol), Mycobacteria (ZN/auramine, Xpert MTB/RIF), Cryptococcus India ink/CrAg, Aspergillus galactomannan, PJP silver, hepatitis serology, HIV, STI NAAT (CT/GC urine), syphilis reverse algorithm, malaria smear, Cryptosporidium acid-fast, C. difficile NAAT + toxin + clinical context, CLSI breakpoints, MALDI-TOF, multiplex PCR panels.

20%

Chemical Pathology

Electrolytes/acid-base (methanol vs salicylate vs DKA AG, osmolar gap), glucose/HbA1c (NGSP/IFCC, altered by RBC lifespan), lipids (Friedewald, direct LDL), hs-troponin (99th percentile + delta), BNP/NT-proBNP (rule-out <100/<300), TSH-reflex, cortisol/cosyntropin, PTH/calcium, lead toxicity (ALA dehydratase/ferrochelatase), acetaminophen Rumack-Matthew, salicylate respiratory alkalosis + AG acidosis, digoxin 0.5-0.9, lithium 0.6-1.2, vanc AUC/MIC 400-600 or trough 15-20, SPEP/IFE, hCG doubling, hemoglobin HPLC, mass spectrometry for vitamin D/steroids/drugs.

9%

Management and Informatics

CLIA test complexity (waived/moderate/high), PT rules (no referral, routine handling), HIPAA TPO + public health + research exceptions, Westgard multi-rules (1_3s, 2_2s, R_4s, 4_1s, 10_x), Levey-Jennings charts, CLSI EP28-A3c reference interval (≥120 samples, 2.5-97.5 percentile), biostatistics (sensitivity/specificity, PPV/NPV, ROC/AUC), Six Sigma DPMO, LOINC/SNOMED/CPT/ICD-10/HCPCS, FDA 2024 LDT rule, CAP/AMP NGS validation (Jennings 2017), lab director CLIA duties, preanalytic quality indicators.

How to Pass the ABPath Clinical Pathology Exam

What You Need to Know

  • Passing score: Criterion-referenced scaled standard (modified Angoff). Pass/fail determined in a single administration.
  • Exam length: 330 questions
  • Time limit: ~6 hours 36 minutes (combined Written/Practical sections)
  • Exam fee: $2,100 CP-only / $2,600 combined AP/CP (ABPath 2026)

Keys to Passing

  • Complete 500+ practice questions
  • Score 80%+ consistently before scheduling
  • Focus on highest-weighted sections
  • Use our AI tutor for tough concepts

ABPath Clinical Pathology Study Tips from Top Performers

1Master the PROPPR 1:1:1 massive transfusion ratio (1 unit RBC : 1 unit FFP : 1 apheresis platelet unit) — tested nearly every exam cycle as the standard approximating whole blood
2Know the HIT 4Ts algorithm and that high probability (≥6) requires immediate heparin cessation (all forms including flushes) with switch to argatroban, bivalirudin, or fondaparinux; diagnosis confirmed by PF4/heparin ELISA then serotonin release assay
3Memorize platelet transfusion thresholds: <10k prophylactic stable, <20k with fever/minor bleeding, <50k for procedures/LP, <100k for neurosurgery or posterior ophthalmic surgery
4Learn the Rumack-Matthew nomogram: acetaminophen level plotted against time post-ingestion (starting at 4 hr, line from 150 μg/mL); above line → NAC. Only valid for single acute ingestion and measured ≥4 hours post-ingestion
5Know Westgard multi-rules: 1_3s and 2_2s reject the run; R_4s indicates random error; 4_1s and 10_x indicate systematic shift/trend. Levey-Jennings charts visualize this — any violation requires root-cause analysis before releasing patient results

Frequently Asked Questions

What is the ABPath Clinical Pathology exam?

The ABPath Clinical Pathology (CP) exam is a primary certification examination offered by the American Board of Pathology for pathologists completing CP-only or combined AP/CP residency training. It is a one-day computer-based exam delivered at Pearson VUE testing centers, with 330 one-best-answer multiple-choice questions in a combined Written/Practical format covering hematopathology, transfusion medicine, medical microbiology, clinical chemistry, and laboratory management/informatics.

How many questions are on the ABPath CP exam and how long is it?

The CP exam contains 330 multiple-choice one-best-answer questions delivered in a combined Written/Practical format over approximately 6 hours 36 minutes. Practical questions include graphs, charts, formulas, diagrams, red cell antibody panels, electropherograms, and calculations. Both written conceptual and practical problem-solving questions are integrated across all content areas.

What is the 2026 ABPath CP blueprint?

The 2026 CP blueprint (effective January 2026) allocates weights: Hematopathology 25%, Blood Banking/Transfusion Medicine 23%, Medical Microbiology 23%, Chemical Pathology 20%, and Management and Informatics 9%. Molecular pathology questions are integrated across all five domains, accounting for 10-15% of the exam overall. Medical microscopy questions may appear in both chemistry and hematopathology subsections.

What is the passing score for the ABPath CP exam?

ABPath uses criterion-referenced scoring with a scaled passing standard set by content experts through a modified Angoff process. Candidates are measured against a fixed content standard, not curved against peers. The pass/fail determination is made in a single administration. Score reports include diagnostic performance by content domain for candidates who need to refocus study before retaking.

What are the eligibility requirements for the ABPath CP exam?

Candidates must hold an MD or DO degree, have completed ACGME-accredited pathology training (CP-only = 3 years; combined AP/CP = 4 years), and maintain an active unrestricted medical or osteopathic license. Applications are submitted via the PATHway portal during the February 16–May 15 window for Fall primary exams (or September–December window for Spring exams).

How much does the ABPath CP exam cost in 2026?

The ABPath primary certification exam fee in 2026 is $2,100 for CP-only or $2,600 for combined AP/CP taken in the same window. The fee includes a $200 non-refundable administrative fee. Candidates taking AP and CP in separate windows pay $2,100 each ($4,200 total). There is no late application fee — applications must be submitted by the May 15 deadline.

What are the highest-yield topics on the ABPath CP exam?

Hematopathology (25%) — master iron studies, PT/aPTT/mixing study interpretation, TTP/ADAMTS13 <10%, HIT 4Ts + PF4 ELISA → SRA, myeloma IMWG, and acute leukemias (APL t(15;17), CML BCR-ABL). Blood Banking (23%) — ABO genetics, DAT/antibody ID, PROPPR 1:1:1 MTP, TRALI vs TACO, DHTR with Kidd antibodies, irradiation indications, RhIG, apheresis ASFA categories. Microbiology (23%) — MRSA mecA, VRE vanA, CRE by carbapenemase type, hepatitis serology, CLSI breakpoints. Chemistry (20%) — acid-base/osmolar gap (methanol, salicylate, EG), Friedewald, hs-troponin, HbA1c, acetaminophen Rumack-Matthew, TDM (vanc AUC, digoxin 0.5-0.9, lithium 0.6-1.2). Management (9%) — CLIA complexity, PT rules, HIPAA, Westgard, LOINC/CPT, FDA 2024 LDT rule.

How should I study for the ABPath CP exam?

Use the official ABPath 2026 CP Blueprint as a roadmap. Build a 12-18 month longitudinal plan through CP/AP-CP residency: rotate through each of the five domains (heme, BB/TM, micro, chem, management) with problem-based learning. Integrate current guidelines: AABB Technical Manual/Standards (21st ed), IDSA infection treatment, CLSI M100 breakpoints (annual updates), ADA/AHA-ACC biomarker recommendations, CAP/AMP NGS validation, and the 2024 FDA LDT rule. Practice interpreting antibody panels, Levey-Jennings charts, and calculations (Friedewald, Rumack-Matthew, AUC/MIC).